samedan logo

home > news > detailed info

FUJIFILM Irvine Scientific Acquires Exclusive License for Artificial Intelligence for IVF

FUJIFILM  Irvine Scientific

The Company looks to expand the use of AI in efforts to improve IVF success

SANTA ANA, Calif., June 22, 2022
: FUJIFILM Irvine Scientific, Inc., a world leader in the innovation, development, and manufacture of cell culture media and assisted reproductive technologies (ART), today announced it has exclusively licensed the intellectual property relating to artificial intelligence (AI) for image-based evaluation of human embryos to improve in-vitro fertilization (IVF) success rates. The technology was developed and patented jointly by investigators from Brigham and Women’s Hospital and Massachusetts General Hospital with expertise in artificial intelligence, biomedical engineering and IVF. Terms of the deal were not disclosed.

FUJIFILM Irvine Scientific plans to offer non-exclusive licensing of the technology to companies wishing to advance the use of AI and image-based tools in reproductive healthcare and will immediately be seeking agreements, globally. This image-based technology has the fundamentally enabling advantage of no capital investment while seamlessly merging into existing IVF workflows. The technology requires no special or specific imaging equipment and provides laboratories with the potential for an easier and lower-cost entry point for implementing AI and image analysis into their workflows. FUJIFILM Irvine Scientific, as the exclusive licensee, has a mission to bring this technology to every clinic around the world.

“Already a leading company of AI and medical imaging, Fujifilm will look for synergies across its healthcare companies to develop innovative applications that leverage this technology,” said Yutaka Yamaguchi, chief executive officer and chairman of FUJIFILM Irvine Scientific, general manager of Fujifilm Life Science Business Division. “Together we will continue to discover new ways to use imaging and artificial intelligence to improve healthcare.”

“AI will be a critical tool for the transformation of clinical procedures to be more objective and reliable,” said Hadi Shafiee, Ph.D., of the Division of Engineering in Medicine, Brigham and Women’s Hospital. “The utility, versatility, and robustness of our AI system in the IVF clinic has been repeatedly demonstrated in numerous international scientific publications, with our most recent work in Nature Biomedical Engineering highlighting its domain adaptability and reliability.”

“Considering how important an IVF cycle is to the patient, each step in the process is critical. Embryologists make dozens of decisions that impact the success of that cycle. With assistance from our AI system, embryologists will have a valuable tool to use in their effort to identify and select embryos with the highest chance of resulting in pregnancy.” said co-inventor Charles Bormann, Ph.D., IVF laboratory director, Massachusetts General Hospital.

“Tools to assist with embryo selection are only the beginning. Development and testing of applications to support the selection of oocytes, sperm, and genetic assessment are in progress,” said Steve Geimer, executive director of the Medical Business Unit, FUJIFILM Irvine Scientific. “Offering non-exclusive licensing to other companies will enable image-based AI to become an industry-standard in IVF and reproductive healthcare.”

Co-inventors of the technology developed by investigators at Brigham and Women’s Hospital and Massachusetts General Hospital, include Manoj Kumar Kanakasabapathy, MS, Research Scientist, and Prudhvi Thirumalaraju, MS, both of the Brigham and Women’s Hospital’s Division of Engineering in Medicine.
phone +3 53 1 281 9920
email Unit 31, Newtown Business & Enterprise Park Newtownmountkennedy, Co. Wicklow
Print this page
Send to a friend
News and Press Releases

Datwyler Launches 5/8-Inch Rigid Needle Shield, Infusion Discs

Altdorf, Switzerland, 11 July 2022— Datwyler, a leading manufacturer of elastomer components for pharmaceutical packaging, is expanding its portfolio with two new products to meet evolving patient demands. The new offerings include a 5/8 in. rigid needle shield (RNS) to address the rising need for prefilled syringes to contain vaccines for intramuscular injection, and isoprene rubber discs for infusion therapies.
More info >>

White Papers

Mauritius Island – An Emerging Centre for R&D in Biotechnology and the Life Sciences

CIDP (Centre International de Développement Pharmaceutique)

Mauritius, the tropical island situated in the Indian Ocean and known worldwide for its beautiful beaches, is also internationally recognised for its rule of law, and political and social stability. Over the past few years, the economy has been successfully transitioned from a monocrop to a diversified innovation-driven and knowledge-based economy, resting on agribusiness, export-oriented manufacturing, tourism, financial services, property development and real estate, ICT-BPO, the seafood industry, a free port, logistics and a nascent ocean economy. Emerging sectors such as healthcare and life sciences are presenting some niche areas for the taking, and the enabling environment is being put in place to make it happen - especially in the light of sustained growth within pharmaceutical, medical device, and clinical research. Important international players are already in operation locally as the country has established the appropriate legal and regulatory frameworks based on international norms, for the development of a strong biomedical research sector.
More info >>

Industry Events

Connect in Pharma

14-15 September 2022, Plaexpo, Geneva, Switzerland

The new event driving innovation for pharma and biopharma businesses, Connect in Pharma will unite key players in Pharmaceutical and Biopharmaceutical packaging and production in Geneva on 14 – 15 September 2022.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement